{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:57:30Z","timestamp":1782406650230,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.endien.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T08:37:21Z","timestamp":1662453441000},"page":"509-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epidemiology and resource use in Spanish type 2 diabetes patients without previous cardiorenal disease: CaReMe Spain study summary"],"prefix":"10.1016","volume":"69","author":[{"given":"Antoni","family":"Sicras-Mainar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Sicras-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Hormigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Manito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Alc\u00e1zar-Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Antonio","family":"Botana-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2022.07.005_bib0195","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2022.07.005_bib0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.endinu.2018.08.004","article-title":"en representaci\u00f3n del Grupo de Trabajo de Consensos y Gu\u00edas Cl\u00ednicas Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 update","volume":"65","author":"Gomez-Peralta","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.endien.2022.07.005_bib0205","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1464-5491.2010.03216.x","article-title":"The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010\u20132030","volume":"28","author":"Holman","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.endien.2022.07.005_bib0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es study","volume":"55","author":"Soriguer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.endien.2022.07.005_bib0215","first-page":"1","article-title":"Atlas de la diabetes de la FID actualizaci\u00f3n","year":"2019","journal-title":"Atlas de la Diabetes de la FID"},{"key":"10.1016\/j.endien.2022.07.005_bib0220","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2022.07.005_bib0225","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2022.07.005_bib0230","doi-asserted-by":"crossref","first-page":"e006260","DOI":"10.1161\/CIRCOUTCOMES.119.006260","article-title":"Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases","volume":"13","author":"Zareini","year":"2020","journal-title":"Cir Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.endien.2022.07.005_bib0235","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.diabres.2013.07.004","article-title":"The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study","volume":"101","author":"Faden","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endien.2022.07.005_bib0240","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.07.005_bib0245","first-page":"251","article-title":"Cardiorenal syndrome: pathophysiology","volume":"37","author":"Kumar","year":"2019","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.endien.2022.07.005_bib0250","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.endien.2022.07.005_bib0255","article-title":"Cardiorenal disease is the most common first CV manifestation and associated with increased death risk in T2D patients: a large multinational observational study","author":"Birkeland","year":"2019","journal-title":"In: EASD Annual Meeting"},{"key":"10.1016\/j.endien.2022.07.005_bib0260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.recesp.2014.02.023","article-title":"Economic impact of heart failure according to the effects of kidney failure","volume":"68","author":"Sicras Mainar","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"Suppl. 3","key":"10.1016\/j.endien.2022.07.005_bib0265","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.jval.2019.09.1764","article-title":"Validation and representativeness of the Spanish BIG-PAC database: integrated computerized medical records for research into epidemiology, medicines and health resource use (Real Word Evidence)","author":"Sicras-Mainar","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.endien.2022.07.005_bib0270","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD): World Health Organization. Available from: https:\/\/www.who.int\/classifications-\/atcddd\/en\/ [consulted 25.05.20]."},{"key":"10.1016\/j.endien.2022.07.005_bib0275","unstructured":"Instituto Nacional de Estad\u00edstica 2017. Ganancia media laboral por edad y sexo. Available from: INE: https:\/\/www.ine.es\/dynt3\/inebase\/index.htm?padre=4563&capsel=4563 [accessed 15.05.20]."},{"key":"10.1016\/j.endien.2022.07.005_bib0280","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/07853890.2019.1602734","article-title":"Incidence and prognosis of heart failure in persons with type 2 diabetes compared with individuals without diabetes \u2013 a nation-wide study from Finland in 1996\u20132012","volume":"51","author":"Winell","year":"2019","journal-title":"Ann Med"},{"key":"10.1016\/j.endien.2022.07.005_bib0285","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2337\/dc19-1803","article-title":"Incidence and associations of chronic kidney disease in community participants with diabetes: a 5-year prospective analysis of the EXTEND45 study","volume":"43","author":"Sukkar","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2022.07.005_bib0290","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","author":"Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2022.07.005_bib0295","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.endien.2022.07.005_bib0300","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/dme.13324","article-title":"Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies","volume":"34","author":"Koye","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.endien.2022.07.005_bib0305","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.endien.2022.07.005_bib0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.07.005_bib0315","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2022.07.005_bib0320","first-page":"gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.endien.2022.07.005_bib0325","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2022.07.005_bib0330","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","author":"Heerspink","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.endien.2022.07.005_bib0335","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2022.07.005_bib0340","first-page":"40","article-title":"Empagliflozin and cardio-renal outcomes in patients with type 2 diabetes and cardiovascular disease \u2013 implications for clinical practice","volume":"14","author":"Fitchett","year":"2018","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.endien.2022.07.005_bib0345","doi-asserted-by":"crossref","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","article-title":"Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"9","author":"Arnott","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.endien.2022.07.005_bib0350","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2016.06.061","article-title":"Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure","volume":"68","author":"Johansson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.endien.2022.07.005_bib0355","doi-asserted-by":"crossref","first-page":"e006260","DOI":"10.1161\/CIRCOUTCOMES.119.006260","article-title":"Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study","volume":"13","author":"Zareini","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.endien.2022.07.005_bib0360","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","article-title":"Economic burden of cardiovascular disease in type 2 diabetes: a systematic review","volume":"21","author":"Einarson","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.endien.2022.07.005_bib0365","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2337\/dc19-2137","article-title":"The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study","volume":"dc19213743","author":"Wan","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2022.07.005_bib0370","doi-asserted-by":"crossref","first-page":"e0203992","DOI":"10.1371\/journal.pone.0203992","article-title":"Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System","volume":"13","author":"Goncalves","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.endien.2022.07.005_bib0375","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/13696998.2017.1288127","article-title":"Economic burden of comorbid chronic kidney disease and diabetes","volume":"20","author":"McQueen","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.endien.2022.07.005_bib0380","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/pop.2012.0027","article-title":"Impact of a chronic disease management program on hospital admissions and readmissions in an Australian population Witart disease or diabetes","volume":"16","author":"Hamar","year":"2013","journal-title":"Popul Health Manag"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018022001287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018022001287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:16:32Z","timestamp":1762866992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018022001287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2530018022001287"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2022.07.005","relation":{},"ISSN":["2530-0180"],"issn-type":[{"value":"2530-0180","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and resource use in Spanish type 2 diabetes patients without previous cardiorenal disease: CaReMe Spain study summary","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}